During Wednesday’s Morning trade, Shares of Monsanto Company (NYSE:MON), gained 1.46% to $98.71.
Monsanto Company (MON) declared it will issue the company’s financial results for its fiscal 2016 first quarter and annual research and development pipeline update on Wednesday, Jan. 6, 2016, before market open.
Monsanto will hold a conference call at 8:30 a.m. central time (9:30 a.m. eastern time) in conjunction with the declarement of its results. The call will focus on the company’s results for the first quarter, future expectations, product performance, planned initiatives, long-term growth drivers, an annual update of projects within the R&D pipeline and may comprise a negotiation of other matters related to the company’s business.
Monsanto Company, together with its auxiliaries, provides agricultural products for farmers worldwide. It operates in two segments, Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment produces raw crop seeds, counting corn, soybean, cotton, and canola seeds under the DEKALB, Channel, Asgrow, and Deltapine brands; and vegetable seeds, such as tomato, pepper, melon, cucumber, squash, beans, broccoli, onions, lettuce, and others under the Seminis and De Ruiter brands.
Shares of Dominion Diamond Corp (NYSE:DDC), declined -2.88% to $9.75, during its current trading session.
Dominion Diamond Corporation, issued the following statement in response to the Plan 13D filed by a group of investors counting The K2 Principal Fund, L.P. (the “Group”).
Dominion actively engages with its shareholders and other stakeholders and values constructive input towards the aim of enhancing shareholder value. The Group has requested a meeting with Dominion, and Dominion looks forward to an open dialogue.
The Company’s board and administration team are committed to creating value for our stakeholders and we will continue to take actions to accomplish this aim and position the Company for future growth and success.
Dominion Diamond Corporation engages in the mining and marketing of rough diamonds. It operates through Diavik Diamond Mine and Ekati Diamond Mine segments. The company holds an 88.9% ownership interest in the Ekati group of mineral claims, in addition to a 65.3% ownership interest in other reserves; and a 40% ownership interest in the Diavik group of mineral claims located at Lac de Gras in Northwest Territories, Canada.
Finally, Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), lost -0.79%, and is now trading at $0.500.
Threshold Pharmaceuticals, declared that it has initiated a noteworthy reduction in its workforce in order to focus the company’s financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* (“tarloxotinib”), the company’s novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) licensed from the University of Auckland, New Zealand.
Threshold will reduce its workforce by about two-thirds, resulting in between 20-25 remaining employees. Threshold anticipates the one-time severance-related charge associated with the workforce reduction to be about $2.6 million, which comprises about $0.3 million of non-cash expense related to the extension of the post-termination exercise period for the outstanding vested stock options for the affected employees. The majority of the charges will be paid by the end of the first quarter of 2016.
“We are enacting this reduction in workforce as a result of the recently declared outcomes from our two Phase 3 trials of evofosfamide in which neither trial met its primary endpoint of demonstrating a statistically noteworthy improvement in overall survival,” said Barry Selick, Ph.D., Chief Executive Officer at Threshold. “I would like to express my sincere gratitude to our employees who are being affected by this difficult but necessary action. This is a loss to our Threshold family of talented and dedicated individuals who have worked with integrity and passion towards improving the lives of people living with cancer.”
Threshold Pharmaceuticals, Inc., a biotechnology company, discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma and soft tissue sarcoma; Phase I/II clinical trials for multiple myeloma and pancreatic cancer; and Phase I clinical trials for the treatment of solid tumors, pancreatic cancer, and advanced solid tumors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
